💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

BRIEF-Prometic reacquires plasminogen rights from Hematech

Published 2017-01-05, 07:01 a/m
© Reuters.  BRIEF-Prometic reacquires plasminogen rights from Hematech
LMNL
-

Jan 5 (Reuters) - Prometic Life Sciences Inc PLI.TO :

* Prometic reacquires plasminogen rights from Hematech

* Prometic Life Sciences Inc - regains 100 pct ownership of profits from future sales of plasminogen for congenital deficiency

* Prometic Life Sciences Inc - hematech continues to hold taiwanese rights to ppps as cmo supplier to prometic

* Prometic Life Sciences Inc - consideration for acquiring rights included issuance of 1.7 million shares of prometic to Hematech

* Prometic Life Sciences Inc - amended its licensing agreement originally entered into with Hematech Biotherapeutics Inc in May 2012

* Prometic Life Sciences Inc - consideration included payment of mid-single digit royalty as well as other non-cash considerations to license agreement Source text for Eikon: ID:nCNWmFmqka Further company coverage: PLI.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.